Olr1479 inhibitors represent a distinct class of chemical compounds that are specifically designed to interact with and inhibit the Olr1479 receptor, a member of the olfactory receptor family within the G-protein coupled receptor (GPCR) superfamily. Olfactory receptors, including Olr1479, are primarily responsible for detecting and transducing odorant molecules into neural signals that contribute to the sense of smell. The Olr1479 receptor, like other GPCRs, operates by binding to specific ligands, which then trigger a sequence of intracellular signaling events that ultimately lead to the perception of different odors. Inhibitors of Olr1479 are designed to disrupt this process by binding to the receptor, thereby blocking the natural ligands from activating the receptor. This inhibition can occur through direct competition at the receptor's active site or by binding to allosteric sites, which may induce conformational changes that prevent the receptor from functioning normally.
The chemical development of Olr1479 inhibitors involves a comprehensive approach to optimizing various properties, including the affinity of the inhibitors for the receptor, their selectivity to avoid off-target effects, and their chemical stability. Techniques such as molecular docking and computational modeling are often employed to visualize how potential inhibitors fit into the receptor's binding sites, providing insights that guide the design of more effective compounds. High-throughput screening is another critical tool used to identify promising candidates from large libraries of chemical compounds, which are then refined through structure-activity relationship (SAR) studies. These studies involve modifying the chemical structure of the inhibitors to improve their potency and selectivity, often by altering the core scaffold or functional groups to enhance interactions with the receptor. Additionally, researchers must consider physicochemical properties such as solubility, lipophilicity, and metabolic stability, which are essential for ensuring that the inhibitors can function effectively in various biological environments. The ongoing study and development of Olr1479 inhibitors contribute to a deeper understanding of olfactory signal transduction and the complex mechanisms by which GPCRs mediate cellular responses to external stimuli.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(RS)-Atenolol | 29122-68-7 | sc-204895 sc-204895A | 1 g 10 g | $79.00 $416.00 | 1 | |
Beta-1 adrenergic receptor antagonist, may indirectly modulate GPCR signaling, potentially impacting Olr1479. | ||||||
Candesartan | 139481-59-7 | sc-217825 sc-217825B sc-217825A | 10 mg 100 mg 1 g | $47.00 $94.00 $151.00 | 6 | |
Angiotensin II receptor blocker, can influence GPCR signaling indirectly, affecting Olr1479. | ||||||
Clonidine | 4205-90-7 | sc-501519 | 100 mg | $240.00 | 1 | |
Alpha-2 adrenergic agonist, might alter GPCR signaling indirectly through adrenergic pathways, impacting Olr1479. | ||||||
Eplerenone | 107724-20-9 | sc-203943 sc-203943A | 10 mg 50 mg | $110.00 $624.00 | 4 | |
Mineralocorticoid receptor antagonist, could modulate GPCR signaling indirectly, impacting Olr1479. | ||||||
Felodipine | 72509-76-3 | sc-201483 sc-201483A | 10 mg 50 mg | $91.00 $222.00 | 1 | |
Calcium channel blocker, may affect GPCR signaling indirectly via calcium modulation, impacting Olr1479. | ||||||
Nebivolol | 99200-09-6 | sc-279910 | 100 mg | $803.00 | 1 | |
Beta-1 adrenergic receptor antagonist, could alter GPCR signaling indirectly, impacting Olr1479. | ||||||
Ramipril | 87333-19-5 | sc-205833 sc-205833A sc-205833B sc-205833C sc-205833D | 500 mg 1 g 2 g 5 g 10 g | $179.00 $245.00 $364.00 $733.00 $1254.00 | 1 | |
ACE inhibitor, may influence GPCR signaling indirectly via the renin-angiotensin system, impacting Olr1479. | ||||||
Telmisartan | 144701-48-4 | sc-204907 sc-204907A | 50 mg 100 mg | $72.00 $94.00 | 8 | |
Angiotensin II receptor blocker, can affect GPCR signaling indirectly, potentially impacting Olr1479. | ||||||
Valsartan | 137862-53-4 | sc-220362 sc-220362A sc-220362B | 10 mg 100 mg 1 g | $40.00 $92.00 $122.00 | 4 | |
Angiotensin II receptor antagonist, might modulate GPCR signaling indirectly, impacting Olr1479. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Calcium channel blocker, could influence GPCR signaling indirectly through calcium ion dynamics, impacting Olr1479. | ||||||